Innoviva (INVA) Expected to Post Earnings on Wednesday

Innoviva (NASDAQ:INVA) is projected to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Innoviva to post earnings of $0.5150 per share and revenue of $115.31 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Innoviva Price Performance

Shares of NASDAQ:INVA opened at $21.02 on Tuesday. The business’s 50 day simple moving average is $20.99 and its 200-day simple moving average is $21.86. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 5.13, a price-to-earnings-growth ratio of 3.05 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.01 and a quick ratio of 15.18. Innoviva has a 12 month low of $17.83 and a 12 month high of $25.15.

Wall Street Analysts Forecast Growth

INVA has been the subject of several research reports. Wall Street Zen cut Innoviva from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Zacks Research raised Innoviva from a “strong sell” rating to a “hold” rating in a report on Monday, August 31st. Weiss Ratings downgraded Innoviva from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Cantor Fitzgerald reduced their price objective on Innoviva from $36.00 to $34.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Finally, Oppenheimer started coverage on Innoviva in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $35.00 price objective on the stock. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.25.

Innoviva Company Profile

Innoviva, Inc is a healthcare company focused on developing, commercializing and managing medicines, with an emphasis on respiratory and hospital-based therapies. The company’s business model includes royalty interests in marketed products as well as ownership and investment in companies developing or commercializing innovative treatments.

Innoviva receives royalty revenue from respiratory medicines developed in collaboration with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Relvar/Breo Ellipta.